Frontiers of Longevity Science, Vol. 2

Technological Possibilities of Life Extension
Erscheinungsjahr 2026
ISBN: 978-3-032-32719-2
Verlag: Springer

Buch, Englisch, 532 Seiten, Format (B × H): 155 mm x 235 mm

Reihe: Professional Practice in Governance and Public Organizations

This is the second volume of a three-volume series on . The series unites global experts to map the rapidly expanding field of longevity medicine. Co-edited by David Barzilai, Max Rangeley, Regina R. Monaco, and David Wood, the series bridges molecular mechanisms, translational innovation, economics, and policy. Contributors from geroscience and the social sciences debate a central question: can we merely slow age-related diseases, or can the biology of aging itself be fundamentally changed?

Volume 2,  , explores how breakthroughs in medicine, data science, and bioengineering are turning longer lives into a practical pursuit. Contributors examine current best practices alongside emerging paradigms like precision prevention and AI-driven health systems. Expanding into frontier concepts such as nanotechnology, cryonics, and biostasis, this volume charts the technological landscape where longevity is actively designed.

Zielgruppe

Professional/practitioner

Autoren/Hrsg.

Rangeley, Max

Barzilai, David

Monaco, Regina R.

Wood, David

Fachgebiete

• Sozialwissenschaften Soziologie | Soziale Arbeit Spezielle Soziologie Familiensoziologie
• Technische Wissenschaften Verfahrenstechnik | Chemieingenieurwesen | Biotechnologie Biotechnologie
• Sozialwissenschaften Soziologie | Soziale Arbeit Soziologie Allgemein Demographie, Demoskopie

Inhaltsverzeichnis

Part I. Best practice in contemporary longevity medicine.- Chapter 1. Longevity Medicine: Evidence-Based Best Practices (David Barzilai).- Chapter 2. Staying sharp: the science of slowing down brain aging and preventing dementia (Christin Glorioso).- Chapter 3. Consumer Health and Preventative Medicine: From Wellness to Lifespan (Anmol Kapoor).- Chapter 4. A Precision Data-driven Approach to Longevity Medicine (Luisa Georgiana Baca).- Chapter 5. Extending Healthspan: Synergizing Nutrition, Geroprotectors, and Longevity Therapeutics (Sebastian Brandhorst).- Chapter 6. Bench to Bedside: Is Rapamycin Headed for the docTOR (Dudley Lamming).- Part II. Nanotechnology and longevity.- Chapter 7. The Protein and the Flywheel - Early Atomically Precise Manufacturing And Longevity Applications (Damian Allis).- Chapter 8. Radical Longevity using Advanced Medical Nanorobots (Robert Freitas).- Chapter 9. Artificial Intelligence in Longevity Biotechnology (Dominika Wilczok).- Chapter 10. Robotics and automated data collection in longevity drug development (Mitchell Lee).- Chapter 11. Reversible Cryostasis: A path to technical realization may now be within reach (Alexander German).- Chapter 12. Ultrasound Awakening After Cryogenic Sleep (Enrique Alcalá).- Part III. Multi-system perspectives.- Chapter 13. Multi-Scale Longevity: Defeating aging from cells to embodied human minds, and the future of the species (Léo Pio-Lopez).- Chapter 14. The Human Exposome: Whole-System Health Underpinning Advances in Human Healthspan, Resilience, and Flourishing (Tina Woods).- Chapter 15. Longevity GPS: Designing the Digital Twin as a Compass for Life Extension and Wellbeing (Philippe Gerwill).- Chapter 16. Deaths of Prejudice (Raiany Romanni-Klein).

Über Autor(innen)

Max Rangeley runs a think tank founded by a member of Parliament in the UK and has served on the boards of other think tanks in London and Brussels. He has put an emphasis on the importance of emerging technologies, including organising and moderating the artificial intelligence roundtable discussions in the European Parliament. Max has authored and co-edited several books with Springer Nature, on central banking, trade, artificial intelligence, the future of money and the power of the mind in medicine among other topics. He studied at the London School of Economics, the University of Aberdeen, and HEC Paris.
Dr. David Barzilai is a longevity physician, thought leader in evidence-based best practices, and Founder and CEO of Barzilai Longevity Consulting. A Lecturer at Harvard Medical School, global speaker, and founding faculty member and Trustee of the Geneva College of Longevity Science, he holds an MD and PhD in health services research and is board-certified in lifestyle medicine. Through Agingdoc.com, he serves individuals, executives, and organizations in consulting and advisory roles, translating advances in longevity science into precise, personalized strategies that optimize healthspan and long-term performance.
Dr. Regina R. Monaco is a theoretical chemist with a PhD in chemistry and biochemistry from the University of Texas at Austin. She is a Senior Research Fellow at the City University of New York and a scientific consultant affiliated with the Courant Institute at New York University. She has held fellowships at NASA Ames Research Center, the Santa Fe Institute, the Max Planck Institute for Biophysical Chemistry, and the Aaron Diamond AIDS Research Center. Her research spans mechanistic and thermodynamic studies of biopolymers, including p21, p53, and small-molecule DNA interactions. Her current work focuses on information transfer in complex dynamical networks, with applications to biological and networked systems.
David W. Wood is a futurist and author of 12 books, including , , and . He chairs London Futurists, where he has organized over 350 public events on technoprogressive topics since 2008. David is the executive director of the LEV Foundation and was previously a pioneer in mobile computing, co-founding Symbian and serving as CTO of Accenture Mobility. He holds an M.A. in Mathematics from Cambridge University and completed postgraduate work in the History and Philosophy of Science. He also holds an honorary doctorate from the University of Westminster.